Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro
Open Access
- 24 February 2000
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 7 (5) , 408-416
- https://doi.org/10.1038/sj.gt.3301094
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A Controlled, Phase 1 Clinical Trial to Evaluate the Safety and Effects in HIV-1 Infected Humans of Autologous Lymphocytes Transduced with a Ribozyme that Cleaves HIV-1 RNA. University of California San Diego, La Jolla, CaliforniaHuman Gene Therapy, 1998
- Preclinical Characterization of an Anti-tat Ribozyme for Therapeutic ApplicationHuman Gene Therapy, 1998
- Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studiesGene Therapy, 1998
- Gene Therapy Targeting Peripheral Blood CD34+Hematopoietic Stem Cells of HIV-infected IndividualsHuman Gene Therapy, 1997
- In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1Virology, 1995
- Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymesGene, 1994
- Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme.Proceedings of the National Academy of Sciences, 1992
- RibozymesCurrent Opinion in Biotechnology, 1992
- RNA enzymes (ribozymes) as antiviral therapeutic agentsTrends in Biotechnology, 1990
- Ribozymes as Potential Anti-HIV-1 Therapeutic AgentsScience, 1990